scholarly journals Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Seza Tetikkurt ◽  
Faruk Taş ◽  
Funda Emre ◽  
Şule Özsoy ◽  
Zeki Tolga Bilece
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Treatment Response ◽  
Squamous Cell ◽  
Tumor Recurrence ◽  
Neck Region ◽  
Excisional Biopsy ◽  
Malignant Cell ◽  
Antituberculous Treatment

A 53-year-old man was admitted for tooth mobility. A mass was identified at the tooth base by CT. Histopathology of the excisional biopsy revealed a moderately differentiated squamous cell carcinoma. Many intact neutrophils were observed within the malignant cell cytoplasm. The patient underwent partial maxillectomy and bilateral neck dissection. Significant neutrophilic emperipolesis was detected in the resected material. Four tumor recurrences developed in the head and neck region during follow-up. Surgery and chemoradiotherapy was performed. The latest tumor recurrence occurred in the peripharyngeal and the posterior parotideal region. The patient was started on pembrolizumab therapy and nearly complete treatment response occurred. Pembrolizumab was discontinued due to the adrenal insufficiency and pulmonary tuberculosis that developed as a treatment side effect. Pembrolizumab was commenced again when tumor recurrence occurred. The patient is currently alive with ongoing pembrolizumab and antituberculous treatment. We present this case to remark the presence of a significant neutrophilic emperipolesis in the squamous cell carcinoma of the hard palate and maxilla which is rarely encountered. Emperipolesis may predict tumor behavior and the consequences of immune-modulating treatment response in squamous cell carcinomas of the head and neck in regard to the findings of our case.

scholarly journals Leiomyosarcoma of the Tracheostomy Site in a Patient with History of Laryngeal Squamous Cell Carcinoma

2021 ◽  
pp. 912-917
Author(s):  
Zainub Ajmal ◽  
Abdul Moiz Khan ◽  
Lezah McCarthy ◽  
Allison Lupinetti ◽  
Syed Mehdi
Keyword(s):  
Risk Factors ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
English Literature ◽  
Neck Region ◽  
Multiple Risk Factors ◽  
History Of ◽  
Rare Malignancy

Leiomyosarcoma (LMS) of the trachea is an extremely rare malignancy with only a few reported cases in English literature. As such the diagnosis can be frequently missed or delayed. We present a case of a 69-year-old male who underwent tracheostomy for airway obstruction secondary to glottic squamous cell carcinoma and treated definitely with radiation therapy. Subsequently, the patient developed LMS of the tracheostomy site. The case further details multiple risk factors that could contribute to development of LMS including radiation exposure, prior malignancy, and chronic inflammation. These risk factors have been well established for LMS in other sites but less so in the head and neck region, which is the subject of our discussion. We also review the current guidelines for head and neck as well as limb sarcomas and discussed role of surgery or radiation and their accompanying challenges in management of this rare malignancy.

Mucosal Adenoid Squamous Cell Carcinoma of the Head and Neck

1996 ◽  
Vol 105 (5) ◽  
pp. 409-413 ◽  
Author(s):  
Alfio Ferlito ◽  
Kenneth O. Devaney ◽  
Christopher M. Milroy ◽  
Alessandra Rinaldo ◽  
Antonino Carbone
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Adenosquamous Carcinoma ◽  
Neck Region ◽  
Metastatic Adenocarcinoma ◽  
Head And Neck Region ◽  
Adenoid Cystic ◽  
Basaloid Squamous

Adenoid squamous cell carcinoma is an uncommon variant of squamous cell carcinoma. The lesion is histologically distinctive and it is usually localized on the skin of the head and neck region; it only rarely involves the mucosal sites. The differential diagnoses include adenosquamous carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, basaloid squamous cell carcinoma, and metastatic adenocarcinoma. Surgery is the treatment of choice. The biologic behavior of this neoplasm is more aggressive when it involves mucosal areas, and the prognosis seems worse than that of conventional squamous cell carcinoma.

Squamous cell carcinoma of the head and neck: Management after excisional biopsy of a solitary metastatic neck node

1993 ◽  
Vol 25 (4) ◽  
pp. 619-622 ◽  
Author(s):  
Yvonne Mack ◽  
James T. Parsons ◽  
William M. Mendenhall ◽  
Scott P. Stringer ◽  
Nicholas J. Cassisi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Excisional Biopsy ◽  
Neck Node

scholarly journals Quantification analysis of tissue eosinophilia in squamous cell carcinoma of the head and neck region

2018 ◽  
Vol 7 (1) ◽  
pp. 165 ◽  
Author(s):  
M Sabzijate ◽  
AH Khatibi ◽  
T Ghiasian ◽  
S Rahrotaban ◽  
E Rastegar ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Region ◽  
Head And Neck Region ◽  
Tissue Eosinophilia ◽  
Quantification Analysis

Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma

2015 ◽  
pp. 123-128 ◽  
Author(s):  
Pedro Henrique Isaacsson Velho ◽  
Gilberto Castro ◽  
Christine H. Chung
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Anticancer Agents ◽  
Neck Region ◽  
Hpv Infection ◽  
Pi3k Pathway ◽  
Neck Squamous Cell Carcinoma ◽  
Preclinical Data

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosal epithelia in the head and neck region. The most common risk factors are tobacco use, alcohol consumption, and HPV infection, particularly in the oropharynx. The HPV-positive HNSCC is biologically and clinically distinct from the HPV-negative HNSCC; however, deregulations within the phosphatidylinositol 3-kinase (PI3K) pathway are frequent in both HPV-positive and HPV-negative HNSCC as it is the most frequently altered oncogenic pathway with a gain-of-function in HNSCC. This article reviews the basic biology and clinical data from the trials involving anticancer agents targeting the PI3K pathway in HNSCC. It also discusses the difficulties of translating the preclinical data to tangible clinical efficacy of these agents in patients with HNSCC even when there is significant preclinical data suggesting the PI3K pathway is a promising therapeutic target in HNSCC. We conclude that additional studies to determine appropriate patient selection for the activation of PI3K pathway and to develop targeted agents either as a monotherapy or combination therapy with favorable toxicity profiles are required before a broader clinical application.

Sign in / Sign up

Export Citation Format

Share Document